

OPEN

Effects of Eucalypt Plant Monoterpenes on Koala (*Phascolarctos Cinereus*) Cytokine Expression *In Vitro*

Caroline Marschner*, Mark B. Krockenberger¹ & Damien P. Higgins¹

Protective immunity is crucial for survival of any species, though the koala as a specialist feeder adapted to an exclusive diet of eucalypts that contain plant secondary metabolites of varying toxicity and of immunomodulatory property. Being constantly exposed to such dietary chemicals it raises the question of their immune effects in a specialist eucalypt feeder. This study demonstrates that natural levels of circulating eucalypt plant secondary metabolites have dose dependent *in vitro* effects on cytokine expression of koala peripheral blood mononuclear cells, suggesting a potential trade-off of reduced function in multiple arms of the immune system associated with koala's use of its specialized dietary niche.

Widespread in the Australian landscape, eucalypts comprise an easily accessible food resource for some folivores, such as the koala (*Phascolarctos cinereus*), the ringtail possum (*Pseudocheirus peregrinus*) and greater glider (*Petauroides volans*) that are able to exploit this dietary niche. The koala is able to utilise this resource exclusively for nutrition and shelter¹ even though chemical defences render eucalypt leaves unpalatable, of low nutritional value, and even toxic. Tannin and lignin (up to 30% DM) bind valuable leaf proteins^{2,3} and cell wall carbohydrates⁴ in the gastrointestinal tract of herbivores. Most leaf fats are either indigestible waxes² or toxic terpenoids.

Monoterpenes, an abundant group of terpenoids in eucalypts, are of small molecular weight and highly lipophilic, hence are readily absorbable from the gut wall of eucalypt folivores⁵, and enter the circulation⁵⁻¹⁰. In spite of the specialist strategy of leaf choice to avoid certain plant secondary metabolites (PSMs)¹¹⁻¹⁶, specialist feeders remain exposed to high concentrations of multiple PSMs^{7,9,17}. Those species rely on increased detoxification abilities to maintain their feeding rate¹⁸. A rapid metabolic clearance of eucalypt monoterpenes but also of pharmaceuticals was found in koalas *in vitro* and *in vivo*¹⁹⁻²⁶. Extended oxidative (cytochrome P450, first phase) and conjugative (glucuronosyltransferase, second phase) detoxification pathways were identified in this species²⁷⁻³¹. Metabolites of monoterpenes were found to be exclusively oxidized^{6,32}.

The continuous intake of toxic eucalypt monoterpenes has always been considered as a dangerous trade. Toxicological data on eucalypt monoterpenes are limited but the acute oral toxicity of 1,8-cineole (the main eucalypt oil constituent) in rats is LD₅₀: 2480 mg/kg³³. In much lower concentrations, monoterpenes act as potent immunomodulatory components that can modify the expression of critical immune mediators. *In vivo* studies in mice have shown that monoterpenes s-limonene and myrcene significantly inhibit the production of the cytokines IFN- γ and IL-4 during LPS induced pleurisy³⁴. The production of TNF- α , IL-1 β , IL-4, IL-5, leukotriene and thromboxane³⁵ was strongly suppressed by 1,8-cineole in *in vitro* assays of human lymphocytes and monocytes. The monoterpene p-cymene significantly reduces expression of the cytokines TNF- α , IL-1 β and IL-6 in an *in-vivo* mouse model^{36,37}. Other major eucalypt monoterpenes, such as terpinen-4-ol, α -terpineol significantly suppressed the production of TNF- α , IL-1 β , IL-8 and IL-10³⁸. These cytokines are key signalling glycoproteins that mediate communication between immune cells. Each individual immune-pathway, innate or adaptive (cell-mediated or humoral), relies on critically balanced interactions of particular cytokines^{39,40}, which aim for an optimal immune response towards specific types of pathogens⁴¹ and are involved in all steps of acute and chronic inflammation^{42,43}. Optimal balances are determined by host-pathogen co-evolution that occurs within the context of the host's and pathogen's environment. Thus, changes to host, pathogen or environment can perturb these balances and influence disease outcomes and impacts at individual or population levels.

Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camperdown, 2006, NSW, Australia. *email: cmars3346@uni.sydney.edu.au

Despite the known immunomodulatory actions of monoterpenes in experimental animal models, the immunological consequences of chronic exposure in a specialist eucalypt feeder, or increases to exposure that might be driven by restricted dietary choice, have not been investigated. Although the immune system of koalas is fundamentally similar to that of other mammalian species, it is unclear to what extent the koala's immune cells have adapted to exposure to these compounds. Koalas' lymphatic anatomical structures are comparable to those of other species^{44,45} and animals show a cellular and humoral immune responses following vaccination⁴⁶ or infection^{47,48}. Circulating B:T cell ratios were found to be high⁴⁹ or similar⁵⁰ to that of other mammals and two subclasses of the immunoglobulins, IgG and IgM, have been identified in serum of koalas⁵¹. Koala peripheral blood leukocytes produce typical inflammatory cytokines in response to non-specific (mitogens)⁵² or specific (Chlamydia antigens) activation^{53–55}. It is possible that either the koala immune cells have evolved resistance to the immunomodulatory effects of these substances or that some downregulation of immune system function has not been an evolutionary disadvantage relative to the benefits of access to this plentiful resource. It is important to understand if any evolutionary trade-offs exist as these may become unbalanced in the face of reduced dietary choice with habitat degradation, or introduction of new pathogens such as *Chlamydia* spp.

The aim of the present study was to analyse the effects of naturally encountered plasma concentrations of two major eucalypt monoterpenes, 1,8-cineole and p-cymene, on cytokine expression of koala peripheral blood mono-nuclear cells (PBMCs) in stimulation assays. The specific roles of inflammatory cytokines in pathological processes and their measurability make them a useful tool in immunological studies⁵⁶. Primers for a whole set of koala immune genes, for CD4, CD8 β , IFN- γ , IL-4, IL-6 and IL-10⁵² as well as IL-17A and TNF- α ^{54,55}, have been described previously. In the present study, cytokines promoting the Th1 (IFN- γ), Th2 (IL-10) and Th17 (IL-17A) pathways of the adaptive immune response and the innate immune response (IL-6, TNF- α) were assessed to test the hypothesis that levels of monoterpenes detected in the blood of koalas can reduce cytokine expression of koala immune cells and, therefore, potentially influence innate and adaptive immunity in this species.

Methods and Materials

Stimulation assays. The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations. Experiments were approved by the Animal Ethics Committee of the University of Sydney (Protocol Nr.565) and by the New South Wales Government (Scientific licence SL101290).

Animals used for blood collection for stimulation assays were adult healthy koalas (3 male and 3 female) that are part of a captive population. Animals were kept under same conditions (females and males separated) and fed on the same eucalypt diet. All animals were chlamydia negative and being of NSW/Qld provenance, KoRV A positive.

Blood was taken from koalas under manual restraint, transported on ice and lymphocyte stimulation assays were performed immediately based on established methods^{49,52}, with the following minor modifications.

Isolated PBMCs were washed in PBS (1 \times) and seeded with culture media into 96 well plates in duplicates in concentrations of 5×10^5 cells per well and exposed to half logarithmic serial dilutions of the eucalypt monoterpenes 1,8-cineole (eucalyptol 99%, analytical grade, C80601 ALDRICH, Sigma Aldrich) and p-cymene (99%, analytical grade C121452 ALDRICH, Sigma Aldrich).

Concentrations used in the current study (1,8-cineole: 194 nmol/l, 648 nmol/l, 1940 nmol/l, 6480 nmol/l, p-cymene 74.5 nmol/l, 223 nmol/l, 745 nmol/l, 2230nmol/l) simulated physiological blood levels (1,8-cineole: 194–6480 nmol/l, p-cymene: 74.5–2230 nmol/l) based on naturally occurring blood concentrations determined in another study using 54 free ranging and captive koalas (Marschner *et al.*, 2019, unpublished data).

PBMCs were activated using the PMA/Ionomycin protocols as described in Maher, *et al.*⁵². Positive controls (activated, with no monoterpene exposure) and negative controls (not activated, no monoterpene exposure) were tested on each plate. Controls contained the same concentrations of carrier (0.45% ethanol) as cells exposed to monoterpene. RNA was extracted using the MagJET RNA Purification kit (K2731, Life Sciences Solutions ThermoFisher Scientific) and the “KingFisher™ Duo Prime Purification System” (ThermoFisher Scientific, Australia). Cytokine gene expression RTqPCR was conducted as previously described^{52,57}.

Lymphocyte proliferation assays. Lymphocyte viability was investigated to detect potential cytotoxic effects of 1,8-cineole and p-cymene in relevant concentrations. Based on validation in koalas by Lau⁵⁸ the MTT assay was performed based on manufacturers recommendations (MTT Reagent, 10009591, Sapphire Bioscience Pty. Ltd, Australia). Intracellular NAD(P)H-dependent oxidoreductase enzymes reduce the applied tetrazolium (yellow dye, MTT) to formazan (purple dye). The formation of the formazan is dependent on cell metabolic activity and cell viability. The intensity of dye was read using a SpectraMax 250 micro-plate reader (Molecular Devices, Bio-Strategy Pty. Ltd. VIC 3061, Australia).

Statistical methods. A linear mixed model was utilized, fitted with a REML, using GenStat (Version 18th, VSN international). Logarithmic values of cytokine up-regulation were used for analysis and model-based means were later back-transformed, including appropriate delta-method standard errors. Toxin type (1,8-cineole, p-cymene) and toxin concentration (1,8-cineole: 194 nmol/l, 648 nmol/l, 1940 nmol/l, 6480 nmol/l, p-cymene 74.5 nmol/l, 223 nmol/l, 745 nmol/l, 2230 nmol/l), as well as their interaction, were treated as fixed effects for each model. To take the positive control into account, additional terms for treatment (yes vs no) were included in the model, with the toxin, concentration and interaction terms nested within it. Additionally correlations between the cytokines were evaluated using two-sided test.




Figure 1. Illustrates the inhibitory effects of p-cymene and 1,8-cineole on up-regulation of cytokines in PBMCs of captive koalas ($n = 6$, 3 males:3 females). Graphs indicate the fold increase of up-regulation (including median with interquartiles) of IL-17, IL-6, IL-10, IFN- γ and TNF- α in PBMCs after stimulation using PMA/Ionomycin while exposed to different concentrations (in nmol/l) of the monoterpenes p-cymene (light grey) and 1,8-cineole (dark grey). Positive control is marked as column (black) at concentration zero, showing the up-regulation of IL-17A, IL-6, IL-10, IFN- γ and TNF- α of stimulated PBMCs without exposure to monoterpenes but only carrier. Error bars indicate standard errors.

Results

No cytotoxic effects were found for monoterpene concentrations used in this study (t -test: $P_{1,8\text{-cineole}} = 0.784$, $P_{p\text{-cymene}} = 0.979$). For every cytokine there was a dose-dependent reduction in cytokine gene expression, regardless of the toxin (1,8-cineole/p-cymene, $P < 0.001$) (Fig. 1). There was a significant effect of toxin type on cytokine expression (all $P \leq 0.020$) except for TNF- α ($P = 0.92$): expression of IL-17A gene was significantly more inhibited by p-cymene treatment compared to 1,8-cineole ($P = 0.002$) whereas 1,8-cineole treatment more effectively reduced expression of all other cytokines (IFN- γ $P = < 0.001$, IL-6 $P = < 0.001$, IL-10 $P = 0.020$). There were no significant difference between the shapes of the dose-response curves (on the logarithmic scale).

A two-sided t -test was used to test for significant correlations between cytokine expression. A significant correlation was found for TNF- α with several cytokines TNF- α /IL-6 ($P_{\text{corr TNF-}\alpha/\text{IL6}} = 0.012$), TNF/IL-17A ($P_{\text{corr TNF-}\alpha/\text{IL17A}} < 0.001$) and TNF- α /IL-10 ($P_{\text{corr TNF-}\alpha/\text{IL-10}} < 0.001$), but also for IL-6 and IL-10 ($P_{\text{corr IL-6/IL-10}} < 0.001$).

Discussion

This study shows that koala PBMC are affected by eucalypt monoterpenes in a dose-dependent fashion, similarly to other species. Interestingly, results were comparable to those for humans³⁵, in which concentrations (~9720 nmol/ml) of 1,8-cineol inhibited production of the cytokines TNF-alpha (by 92%), IL-1beta (by 84%), IL-4 (by 70%) and IL-5 (by 65%) in lymphocytes and, in monocytes, TNF-alpha (by 99%), IL-1beta (by 84%), IL-6 (by 76%), and IL-8 (by 65%). P-cymene dose-dependently down-regulated production of IL-6, TNF- α , and IL-1 β in mice^{36,37} and mixtures of relevant eucalypt monoterpenes significantly inhibited production of TNF- α , IL-6, TNF- α , IFN- γ , IL 10, IL-5 and IL-13 in human mononuclear cells⁵⁹.

Other eucalypt monoterpenes have shown similar effects to those of 1,8-cineole and p-cymene. Limonene and β -myrcene reduced IFN- γ and IL-4 production of mononuclear cells significantly in non-toxic concentrations and when orally administered in mice prevented a delayed inflammatory reaction induced by LPS injection into the pleural cavity. A strong inhibition of cell migration of total leucocytes and mononuclear cells was found in this study³⁴. Furthermore the monoterpenes terpinen-4-ol reduced significantly the production of TNF- α and IL-10 in human peripheral blood monocytes after LPS activation³⁸.

Synergistic effects were observed in other studies when monoterpenes were administered in their natural occurring mixtures in form of essential oil extracts of plants which promoted even stronger immunosuppressive effects when compared to the application of single components^{34,60}. Future studies could investigate synergistic effects of eucalypt monoterpenes in their naturally occurring composition in koala blood. Monoterpene profiles were published recently⁶¹.

In the present study p-cymene also had some evidence of stimulatory effects on cytokine expression in the lowest concentrations, though this finding was not consistent in all koalas. Such biphasic dose-responses (hormesis), whereby compounds have stimulatory effects in low doses but become inhibitory with increasing concentrations, are widespread in immunological studies⁶².

It appears that, similar to other species, koala PBMC function is affected by exposure to common eucalypt PSMs and yet, unlike other species, koala PBMC are regularly exposed to PSMs concentrations in order to exploit their dietary niche. This finding opens for consideration the novel perspective that the immunomodulatory effect of dietary toxins may be another important factor limiting the koalas use of particular habitats.

Dietary exposure to the immunomodulatory effects of PSMs might be advantageous if the low metabolic rate of the koala is considered, neutral, or may place constraints on ability to adapt to new pathogens or environmental conditions, making it of interest to explore these relationships further in future studies. Firstly it is possible that, along with lower body temperature and efficient pelt and tissue insulation^{63,64}, PSM exposure has facilitated adaptation to a low energy food source, by limiting some energetically expensive aspects of the immune response. For maintenance, koalas only require 257 to 411KJ/kg^{-0.75} daily⁶⁵, compared to other captive eutherian mammals with approximately 600 KJ/kg^{-0.75}^{66,67}. The initiation of an immune response to kill infectious pathogens increases resting metabolic rate^{68,69} and an induction of fever requires a 7–15% increase in energy requirements for each degree celsius of increase in body temperature⁶⁸. Both the innate and adaptive immune responses are energetically expensive to either develop or maintain^{70,71}. In view of a low energetic budget, immunological trade-offs are not unexpected⁷², would ultimately leave koalas less able to mount some immune responses and might involve one or more of several other alternative resistance or tolerance mechanisms.

The effects of PSMs on PMBC function and potentially immune function, may become more important under climate change or land use scenarios in which eucalypt PSMs increase^{73,74} or with introduction of novel pathogens. It appears likely that at least some strains of *Chlamydia pecorum*, a significant pathogen of koalas^{75,76} that requires specific immune pathways for elimination or control^{77,78}, were brought into Australia with sheep and cattle during European settlement^{79–81} and, based on their impact on individuals and some populations, it appears feasible that koalas may not have the adaptive capacity to deal with this disease. Understanding these issues will require a better understanding of the co-evolutionary relationships between the koala's pathogens and parasites, host responses and diet, and full investigation of this area would need to go beyond aspects of the host response explored in the current study. For example, in addition to more detailed examination of the immune system, the potential for interplay between PSM metabolism and defences based on depletion of pathogen nutrients, such as tryptophan, appear worth examining. Kynurenine pathways are effective modulators of pathogen tolerance by hosts through tryptophan depletion⁸². *Chlamydia pneumoniae*, which has a long evolutionary history with koalas and produces little disease⁸³, lacks a specific tryptophan synthesis pathway and consequently is dependent on host tryptophan resources⁸⁴, unlike *C. pecorum*, which exhibits a nearly complete biosynthetic pathway⁸⁵. Kynurenines, products of tryptophan catabolism, induce Cytochrome P450 metabolism of xenobiotics such as PSMs through aryl hydrocarbon receptors (AhRs)⁸⁶ and also allow the differentiation of regulatory T cells^{87,88} and restrict dendritic cell maturation^{89,90}. Alternatively, monoterpenes have been shown to be antibacterial and antifungal^{91–94}. There is currently no evidence they are protective in naturally occurring blood concentrations^{95,96} but act at least locally in the respiratory and oral tract through eucalypt oil ingestion^{97–100}.

Conclusions

A dose-dependent inhibition of cytokine expression *in vitro* was found in this study when koala PBMCs were activated in the presence of naturally occurring concentrations of two major eucalypt monoterpenes, 1,8-cineole and p-cymene. This finding opens a new area for future enquiry relevant to folivore and herbivore ecology and evolution: that of the role of dietary toxins in immunological trade-offs. Currently it is unclear the role that eucalypt monoterpenes play in koalas' immune resilience and fundamental research is needed in koala eco-immunology, to investigate the potential significance of any trade-offs to resilience of koala populations in response to changing environments and pathogens, particularly *Chlamydia* species.

Received: 2 August 2018; Accepted: 12 October 2019;

Published online: 12 November 2019

References

1. Martin, R. & Handasyde, K. A. *The koala: natural history, conservation and management*. (UNSW Press, 1999).
2. Archer, M. & Cronin, L. *Koala: Australia's endearing marsupial*. (Reed Books Pty, Limited, 1987).
3. Hume, I. D. *Marsupial nutrition*. (Cambridge University Press, 1999).
4. Van Soest, P. Plant fiber and its role in herbivore nutrition. *The Cornell Veterinarian* **67**, 307 (1977).
5. Foley, W., Lassak, E. & Brophy, J. Digestion and absorption of Eucalyptus essential oils in greater glider (*Petauroides volans*) and brushtail possum (*Trichosurus vulpecula*). *Journal of chemical ecology* **13**, 2115–2130 (1987).

6. Boyle, R., McLean, S., Foley, W. J. & Davies, N. W. Comparative Metabolism of Dietary Terpene, p-Cymene, in Generalist and Specialist Folivorous Marsupials. *Journal of Chemical Ecology* **25**, 2109–2126, <https://doi.org/10.1023/A:1021092908058> (1999).
7. Boyle, R. R. *The metabolic fate of dietary terpenes in folivorous marsupials*, University of Tasmania (1999).
8. Boyle, R. R. & McLean, S. Constraint of feeding by chronic ingestion of 1,8-cineole in the brushtail possum (*Trichosurus vulpecula*). *Journal of chemical ecology* **30**, 757–775, <https://doi.org/10.1023/B:JOEC.0000028430.92739.83> (2004).
9. Boyle, R. R., McLean, S., Brandon, S. & Wiggins, N. Rapid Absorption of Dietary 1,8-Cineole Results in Critical Blood Concentration of Cineole and Immediate Cessation of Eating in the Common Brushtail Possum (*Trichosurus vulpecula*). *Journal of Chemical Ecology* **31**, 2775–2790, <https://doi.org/10.1007/s10886-005-8393-0> (2005).
10. McLean, S., Boyle, R., Brandon, S., Davies, N. & Sorensen, J. Pharmacokinetics of 1, 8-cineole, a dietary toxin, in the brushtail possum (*Trichosurus vulpecula*): significance for feeding. *Xenobiotica* **37**, 903–922 (2007).
11. Hindell, M. & Lee, A. Habitat use and tree preferences of koalas in a mixed eucalypt forest. *Wildlife Research* **14**, 349–360 (1987).
12. Lawler, I. R., Foley, W. J., Eschler, B. M., Pass, D. M. & Handasyde, K. Intraspecific variation in Eucalyptus secondary metabolites determines food intake by folivorous marsupials. *Oecologia* **116**, 160–169, <https://doi.org/10.1007/s004420050575> (1998).
13. Lawler, I. R., Foley, W. J. & Eschler, B. M. Foliar concentration of a single toxin creates habitat patchiness for a marsupial folivore. *Ecology* **81**, 1327–1338 (2000).
14. Moore, B. D. & Foley, W. J. A review of feeding and diet selection in koalas (*Phascolarctos cinereus*). *Australian Journal of Zoology* **48**, 317–333 (2000).
15. Moore, B. D. & Foley, W. J. Tree use by koalas in a chemically complex landscape. *Nature* **435**, 488–490, http://www.nature.com/nature/journal/v435/n7041/supinfo/nature03551_S1.html (2005).
16. Moore, B. D., Foley, W. J., Wallis, I. R., Cowling, A. & Handasyde, K. A. *Eucalyptus* foliar chemistry explains selective feeding by koalas. *Biology Letters* **1**, 64–67 (2005).
17. McLean, S. *et al.* Glucuronuria in the koala. *Journal of chemical ecology* **29**, 1465–1477 (2003).
18. Marsh, K. J., Wallis, I. R., Andrew, R. L. & Foley, W. J. The detoxification limitation hypothesis: where did it come from and where is it going? *Journal of Chemical Ecology* **32**, 1247–1266, <https://doi.org/10.1007/s10886-006-9082-3> (2006).
19. Pass, M. & Brown, A. Liver function in normal koalas and macropods. *Australian veterinary journal* **67**, 151–152 (1990).
20. McLean, S. & Foley, W. J. Metabolism of *Eucalyptus* terpenes by herbivorous marsupials. *Drug Metabolism Reviews* **29**, 213–218, <https://doi.org/10.3109/03602539709037582> (1997).
21. Liapis, P., Pass, G. J., McKinnon, R. A. & Stupans, I. Characterisation of tolbutamide hydroxylase activity in the common brushtail possum, (*Trichosurus vulpecula*) and koala (*Phascolarctos cinereus*): inhibition by the eucalyptus terpene 1, 8-cineole. *Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology* **127**, 351–357 (2000).
22. Pass, G. J., McLean, S., Stupans, I. & Davies, N. Microsomal metabolism of the terpene 1,8-cineole in the common brushtail possum (*Trichosurus vulpecula*), koala (*Phascolarctos cinereus*), rat and human. *Xenobiotica* **31**, 205–221, <https://doi.org/10.1080/00498250110043535> (2001).
23. Kimble, B. *et al.* Pharmacokinetics of meloxicam in koalas (*Phascolarctos cinereus*) after intravenous, subcutaneous and oral administration. *Journal of veterinary pharmacology and therapeutics* **36**, 486–493 (2013).
24. Black, L., Krockenberger, M., Kimble, B. & Govendir, M. Pharmacokinetics of fluconazole following intravenous and oral administration to koalas (*Phascolarctos cinereus*). *Journal of veterinary pharmacology and therapeutics* **37**, 90–98 (2014).
25. Black, L., Landersdorfer, C., Bulitta, J., Griffith, J. & Govendir, M. Evaluation of enrofloxacin use in koalas (*Phascolarctos cinereus*) via population pharmacokinetics and Monte Carlo simulation. *Journal of veterinary pharmacology and therapeutics* **37**, 301–311 (2014).
26. Kimble, B. *et al.* *In vitro* hepatic microsomal metabolism of meloxicam in koalas (*Phascolarctos cinereus*), brushtail possums (*Trichosurus vulpecula*), ringtail possums (*Pseudocheirus peregrinus*), rats (*Rattus norvegicus*) and dogs (*Canis lupus familiaris*). *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* **161**, 7–14 (2014).
27. Ngo, S., Kong, S., Kirlich, A., McKinnon, R. A. & Stupans, I. Cytochrome P450 4A, peroxisomal enzymes and nicotinamide cofactors in koala liver. *Comparative Biochemistry and Physiology - C Toxicology and Pharmacology* **127**, 327–334 (2000).
28. Liapis, P., Pass, G. J., McKinnon, R. A. & Stupans, I. Characterisation of tolbutamide hydroxylase activity in the common brushtail possum, (*Trichosurus vulpecula*) and koala (*Phascolarctos cinereus*): Inhibition by the Eucalyptus terpene 1,8-cineole. *Comparative Biochemistry and Physiology - C Toxicology and Pharmacology* **127**, 351–357 (2000).
29. Ngo, S. N. T., McKinnon, R. A. & Stupans, I. Cloning and expression of koala (*Phascolarctos cinereus*) liver cytochrome P450 CYP4A15. *Gene* **376**, 123–132, <https://doi.org/10.1016/j.gene.2006.02.020> (2006).
30. Jones, B. R., El-Merhibi, A., Ngo, S. N. T., Stupans, I. & McKinnon, R. A. Hepatic cytochrome P450 enzymes belonging to the CYP2C subfamily from an Australian marsupial, the koala (*Phascolarctos cinereus*). *Comparative Biochemistry and Physiology, Part C* **148**, 230–237, <https://doi.org/10.1016/j.cbpc.2008.05.020> (2008).
31. Johnson, R. N. *et al.* Adaptation and conservation insights from the koala genome. *Nature Genetics* **50**, 1102–1111, <https://doi.org/10.1038/s41588-018-0153-5> (2018).
32. McLean, S. *et al.* Metabolic fate of dietary terpenes from *Eucalyptus radiata* in common ringtail possum (*Pseudocheirus peregrinus*). *Journal of chemical ecology* **19**, 1625–1643, <https://doi.org/10.1007/BF00982297> (1993).
33. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic acids research* **46**, D1074–d1082, <https://doi.org/10.1093/nar/gkx1037> (2018).
34. Souza, M., Siani, A., Ramos, M., Menezes-de-Lima, O. Jr. & Henriques, M. Evaluation of anti-inflammatory activity of essential oils from two Asteraceae species. *Die Pharmazie-An International Journal of Pharmaceutical Sciences* **58**, 582–586 (2003).
35. Juergens, U. R. *et al.* Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes. *Pulmonary pharmacology & therapeutics* **17**, 281–287, <https://doi.org/10.1016/j.pupt.2004.06.002> (2004).
36. Xie, G. *et al.* p-Cymene protects mice against lipopolysaccharide-induced acute lung injury by inhibiting inflammatory cell activation. *Molecules* **17**, 8159–8173 (2012).
37. Chen, L., Zhao, L., Zhang, C. & Lan, Z. Protective effect of p-cymene on lipopolysaccharide-induced acute lung injury in mice. *Inflammation* **37**, 358–364, <https://doi.org/10.1007/s10753-013-9747-3> (2014).
38. Hart, P. H. *et al.* Terpinen-4-ol, the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. *Inflammation Research* **49**, 619–626, <https://doi.org/10.1007/s000110050639> (2000).
39. Miossec, P. *In T Cells in Arthritis* 93–109 (Springer, 1998).
40. Kidd, P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. *Alternative medicine review* **8**, 223–246 (2003).
41. Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L. & Sher, A. Role of Cytokines and CD4+ T-Cell Subsets in the Regulation of Parasite Immunity and Disease. *Immunological reviews* **112**, 161–182 (1989).
42. Feghali, C. A. & Wright, T. M. Cytokines in acute and chronic inflammation. *Front Biosci* **2**, d12–d26 (1997).
43. Luster, A. D. Chemokines — Chemotactic Cytokines That Mediate Inflammation. *New England Journal of Medicine* **338**, 436–445, <https://doi.org/10.1056/nejm199802123380706> (1998).
44. Hanger, J. J. & Heath, T. J. Topography of the major superficial lymph nodes and their efferent lymph pathways in the koala (*Phascolarctos cinereus*). *Journal of anatomy* **177**, 67 (1991).

45. Hanger, J. J. & Heath, T. J. The arrangement of gut-associated lymphoid tissues and lymph pathways in the koala (*Phascolarctos cinereus*). *Journal of anatomy* **185**, 129 (1994).
46. Carey, A. J. *et al.* ORIGINAL ARTICLE: A Multi-Subunit Chlamydial Vaccine Induces Antibody and Cell-Mediated Immunity in Immunized Koalas (*Phascolarctos cinereus*): Comparison of Three Different Adjuvants. *American Journal of Reproductive Immunology* **63**, 161–172, <https://doi.org/10.1111/j.1600-0897.2009.00776.x> (2010).
47. Girjes, A. A., Ellis, W. A. H., Carrick, F. N. & Lavin, M. F. Some aspects of the immune response of koalas (*Phascolarctos cinereus*) and *in vitro* neutralization of chlamydia psittaci (koala strains). *FEMS Immunology and Medical Microbiology* **6**, 21–30 (1993).
48. Higgins, D. P., Hemsley, S. & Canfield, P. J. Association of Uterine and Salpingeal Fibrosis with Chlamydial Hsp60 and Hsp10 Antigen-Specific Antibodies in Chlamydia-Infected Koalas. *Clinical and Diagnostic Laboratory Immunology* **12**, 632–639, <https://doi.org/10.1128/CDLI.12.5.632-639.2005> (2005).
49. Lau, Q., Canfield, P. J. & Higgins, D. P. Expression and *in vitro* upregulation of MHCII in koala lymphocytes. *Veterinary Immunology and Immunopathology* **147**, 35–43, <https://doi.org/10.1016/j.vetimm.2012.04.010> (2012).
50. Wilkinson, R., Kotlarski, I. & Barton, M. Further characterisation of the immune response of the koala. *Veterinary immunology and immunopathology* **40**, 325–339 (1994).
51. Wilkinson, R., Allanson, M., Kolega, V., Lawrence, D. & Neville, S. Purification and initial characterisation of koala immunoglobulins. *Veterinary immunology and immunopathology* **29**, 189–195 (1991).
52. Maher, I. E., Griffith, J. E., Lau, Q., Reeves, T. & Higgins, D. P. Expression profiles of the immune genes CD4, CD8 β , IFN γ , IL-4, IL-6 and IL-10 in mitogen-stimulated koala lymphocytes (*Phascolarctos cinereus*) by qRT-PCR. *PeerJ* **2**, e280 (2014).
53. Mathew, M. *et al.* Molecular characterisation and expression analysis of Interferon gamma in response to natural Chlamydia infection in the koala, *Phascolarctos cinereus*. *Gene* **527**, 570–577, <https://doi.org/10.1016/j.gene.2013.06.019> (2013).
54. Mathew, M., Beagley, K. W., Timms, P. & Polkinghorne, A. Preliminary characterisation of tumor necrosis factor alpha and interleukin-10 responses to Chlamydia pecorum infection in the koala (*Phascolarctos cinereus*). *Plos one* **8**, e59958 (2013).
55. Mathew, M., Waugh, C., Beagley, K. W., Timms, P. & Polkinghorne, A. Interleukin 17A is an immune marker for chlamydial disease severity and pathogenesis in the koala (*Phascolarctos cinereus*). *Developmental & Comparative Immunology* **46**, 423–429 (2014).
56. Bradley, J. & Jackson, J. Measuring immune system variation to help understand host-pathogen community dynamics. *Parasitology-Cambridge* **135**, 807 (2008).
57. Maher, I. E. & Higgins, D. P. Altered Immune Cytokine Expression Associated with KoRV B Infection and Season in Captive Koalas. *PLOS ONE* **11**, e0163780, <https://doi.org/10.1371/journal.pone.0163780> (2016).
58. Lau, Q. *Expression and diversity of major histocompatibility complex class II (MHCII) of koalas* PhD thesis, University of Sydney (2013).
59. Hammer, K. A. *et al.* Antimicrobial and anti-inflammatory activity of five Taxandria fragrans oils *in vitro*. *Microbiology and immunology* **52**, 522–530 (2008).
60. Moretti, M. D. L., Peana, A. T. & Satta, M. A Study on Anti-Inflammatory and Peripheral Analgesic Action of Salvia sclarea Oil and Its Main Components. *Journal of Essential Oil Research* **9**, 199–204, <https://doi.org/10.1080/10412905.1997.9699459> (1997).
61. Marschner, C., Krockenberger, M. B., Higgins, D. P., Mitchell, C. & Moore, B. D. Ingestion and Absorption of Eucalypt Monoterpenes in the Specialist Feeder, the Koala (*Phascolarctos cinereus*). *Journal of chemical ecology*. <https://doi.org/10.1007/s10886-019-01097-x> (2019).
62. Calabrese, E. J. Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implications. *Critical reviews in toxicology* **35**, 89–295 (2005).
63. Hulbert, A. & Dawson, T. Thermoregulation in perameloid marsupials from different environments. *Comparative Biochemistry and Physiology Part A: Physiology* **47**, 591–616 (1974).
64. Degabriele, R. & Dawson, T. Metabolism and heat balance in an arboreal marsupial, the koala (*Phascolarctos cinereus*). *Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology* **134**, 293–301 (1979).
65. Ullrey, D. & Robinson, P. & Whetter, P. Eucalyptus Digestibility and Digestible Energy Requirements of Adult Male Koalas, *Phascolarctos Cinereus* (Marsupialia). *Australian Journal of Zoology* **29**, 847–852, <https://doi.org/10.1071/ZO9810847> (1981).
66. Evans, E. & Miller, D. S. Comparative nutrition, growth and longevity. *The Proceedings of the Nutrition Society* **27**, 121–129, <https://doi.org/10.1079/PNS19680036> (1968).
67. Robbins, C. T. *Wildlife feeding and nutrition*. (Academic Press, 1983).
68. Demas, G. E., Chefer, V., Talan, M. I. & Nelson, R. J. Metabolic costs of mounting an antigen-stimulated immune response in adult and aged C57BL/6J mice. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* **273**, R1631–R1637 (1997).
69. Martin, L. B., Scheuerlein, A. & Wikelski, M. Immune activity elevates energy expenditure of house sparrows: a link between direct and indirect costs? *Proceedings of the Royal Society of London. Series B: Biological Sciences* **270**, 153–158, <https://doi.org/10.1098/rspb.2002.2185> (2003).
70. Lee, K. A. Linking immune defenses and life history at the levels of the individual and the species. *Integrative and Comparative Biology* **46**, 1000–1015, <https://doi.org/10.1093/icb/icl049> (2006).
71. Rauw, W. M. Immune response from a resource allocation perspective. *Should we aim for genetic improvement in host resistance or tolerance to infectious disease?*, 48 (2012).
72. Viney, M. E., Riley, E. M. & Buchanan, K. L. Optimal immune responses: immunocompetence revisited. *Trends in Ecology & Evolution* **20**, 665–669 (2005).
73. Heiden, A. *et al.* Emission of volatile organic compounds from ozone-exposed plants. *Ecological Applications, Washington, DC* **9**, 1160–1167 (1999).
74. Constable, J. V. H., Guenther, A. B., Schimel, D. S. & Monson, R. K. Modelling changes in VOC emission in response to climate change in the continental United States. *Global Change Biology* **5**, 791–806, <https://doi.org/10.1046/j.1365-2486.1999.00273.x> (1999).
75. Krockenberger, M. & Higgins, D. In *Wildlife Pathology Short Course 2012*. 208–215. (Australian Registry of Wildlife Health).
76. Griffith, J. E., Dhand, N. K., Krockenberger, M. B. & Higgins, D. P. A retrospective study of admission trends of koalas to a rehabilitation facility over 30 years. (2013).
77. Johansson, M., Schön, K., Ward, M. & Lycke, N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. *Infection and immunity* **65**, 1032–1044 (1997).
78. Lampe, M. F., Wilson, C. B., Bevan, M. J. & Starnbach, M. N. Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection. *Infection and immunity* **66**, 5457–5461 (1998).
79. Brown, A. S., Carrick, F. N., Gordon, G. & Reynolds, K. The diagnosis and epidemiology of an infertility disease in the female koala. *Veterinary Radiology* **25**, 242–248 (1984).
80. Jelocnik, M., Frentiu, F. D., Timms, P. & Polkinghorne, A. Multilocus sequence analysis provides insights into molecular epidemiology of Chlamydia pecorum infections in Australian sheep, cattle, and koalas. *Journal of clinical microbiology* **51**, 2625–2632 (2013).
81. Bachmann, N. L. *et al.* Comparative genomics of koala, cattle and sheep strains of Chlamydia pecorum. *BMC Genomics* **15**, 667, <https://doi.org/10.1186/1471-2164-15-667> (2014).

82. Chen, Y. & Guillemin, G. J. Kynurenine pathway metabolites in humans: disease and healthy states. *International Journal of Tryptophan Research* **2**, 1 (2009).
83. Jackson, M., White, N., Giffard, P. & Timms, P. Epizootiology of Chlamydia infections in two free-range koala populations. *Veterinary Microbiology* **65**, 255–264, [https://doi.org/10.1016/S0378-1135\(98\)00302-2](https://doi.org/10.1016/S0378-1135(98)00302-2) (1999).
84. Kalman, S. *et al.* Comparative genomes of Chlamydia pneumoniae and C. trachomatis. *Nature genetics* **21**, 385–389 (1999).
85. Mojica, S. *et al.* Genome sequence of the obligate intracellular animal pathogen Chlamydia pecorum E58. *Journal of bacteriology* **193**, 3690–3690 (2011).
86. Stone, T. W., Stoy, N. & Darlington, L. G. An expanding range of targets for kynurenine metabolites of tryptophan. *Trends in Pharmacological Sciences* **34**, 136–143, <https://doi.org/10.1016/j.tips.2012.09.006> (2013).
87. Fallarino, F. *et al.* The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ -chain and induce a regulatory phenotype in naive T cells. *The Journal of Immunology* **176**, 6752–6761 (2006).
88. Mezrich, J. D. *et al.* An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. *The Journal of Immunology* **185**, 3190–3198 (2010).
89. Jux, B., Kadow, S. & Esser, C. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. *The Journal of Immunology* **182**, 6709–6717 (2009).
90. Nguyen, N. T. *et al.* Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. *Proceedings of the National Academy of Sciences* **107**, 19961–19966 (2010).
91. Deans, S. & Ritchie, G. Antibacterial properties of plant essential oils. *International journal of food microbiology* **5**, 165–180 (1987).
92. Pattanaik, S., Subramanyam, V. & Kole, C. Antibacterial and antifungal activity of ten essential oils. *in vitro. Microbios* **86**, 237–246 (1995).
93. Batish, D. R., Singh, H. P., Kohli, R. K. & Kaur, S. Eucalyptus essential oil as a natural pesticide. *Forest Ecology and Management* **256**, 2166–2174, <https://doi.org/10.1016/j.foreco.2008.08.008> (2008).
94. Gilles, M., Zhao, J., An, M. & Agboola, S. Chemical composition and antimicrobial properties of essential oils of three Australian Eucalyptus species. *Food Chemistry* **119**, 731–737, <https://doi.org/10.1016/j.foodchem.2009.07.021> (2010).
95. De Feo, V., Bruno, M., Tahiri, B., Napolitano, F. & Senatore, F. Chemical composition and antibacterial activity of essential oils from Thymus spinulosus Ten. (Lamiaceae). *Journal of agricultural and food chemistry* **51**, 3849–3853, <https://doi.org/10.1021/jf021232f> (2003).
96. Rashid, S., Rather, M. A., Shah, W. A. & Bhat, B. A. Chemical composition, antimicrobial, cytotoxic and antioxidant activities of the essential oil of Artemisia indica Willd. *Food Chemistry* **138**, 693–700, <https://doi.org/10.1016/j.foodchem.2012.10.102> (2013).
97. Roomiani, L. & Roomiani, M. Chemical Composition and Antibacterial Activity of Essential Oil from (Rosmarinus Officinalis) and (Mentha Spicata) Against Oral Pathogens. *Iranian Journal Of Public Health* **43**, 32–32 (2014).
98. Yang, C., Hu, D. H. & Feng, Y. Antibacterial activity and mode of action of the Artemisia capillaris essential oil and its constituents against respiratory tract infection-causing pathogens. *Molecular medicine reports* **11**, 2852–2860, <https://doi.org/10.3892/mmr.2014.3103> (2015).
99. Horváth, G. & Ács, K. Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review. *Flavour and Fragrance Journal* **30**, 331–341, <https://doi.org/10.1002/ffj.3252> (2015).
100. Tong-Hong, W. *et al.* Evaluation of the Antibacterial Potential of Liquid and Vapor Phase Phenolic Essential Oil Compounds against Oral Microorganisms. *PLoS One* **11**, e0163147, <https://doi.org/10.1371/journal.pone.0163147> (2016).

Acknowledgements

WILDLIFE Sydney Zoo for their cooperation and provision of captive koalas for blood sampling, A/Prof. Peter Thompson for statistical analysis, Maira Meggiolaro and Iona Maher for support and advice on laboratory techniques. This study was supported by Whitehead bequest and Caroline Marschner's position partially funded by the Koala Health Hub, University of Sydney.

Author contributions

Caroline Marschner; design of experiments, sample collection and analysis, data curation, data visualization, interpretation of results, writing of original manuscript. Damien Higgins; supervision, resources, methodology, interpretation of results, writing-review and editing. Mark Krockenberger; supervision, resources, interpretation of results, writing-review and editing.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to C.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019